Can the sequence of chemotherapy regimens influence outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?

被引：1
|
作者：
Schmidt, Shannon Leah
Durkal, Vipal
Jayavalsan, Shinoj Pattali
Ritch, Paul S.
Thomas, James P.
Erickson, Beth
Christians, Kathleen K.
Tsai, Susan
Evans, Douglas B.
George, Ben
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Froedtert Hosp, Milwaukee, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.428
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
428
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?
    Jayavalsan, Shinoj Pattali
    Schmidt, Shannon Leah
    Durkal, Vipal
    Ritch, Paul S.
    Thomas, James P.
    Erickson, Beth
    Christians, Kathleen K.
    Tsai, Susan
    Evans, Douglas B.
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens
    Anna M. Masellis
    Timothy D. Sielaff
    Gail P. Bender
    International Journal of Clinical Oncology, 2009, 14 : 478 - 481
  • [3] Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens
    Masellis, Anna M.
    Sielaff, Timothy D.
    Bender, Gail P.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (05) : 478 - 481
  • [4] A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.
    Weinberg, Benjamin Adam
    Wang, Hongkun
    Witkiewicz, Agnieszka Katarzyna
    Marshall, John
    Knudsen, Erik S.
    Pishvaian, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Geographic variation in systemic treatment of metastatic pancreatic adenocarcinoma (mPAC) patients in real world across Europe
    Taieb, J.
    Carrato, A.
    AMellbring
    Prager, G.
    Melisi, D.
    Westphalen, B.
    Macarulla Mercade, T.
    D'Esquermes, N.
    Ferreras, A.
    De Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29 : 100 - +
  • [6] First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis
    Zhang, Shuisheng
    Xie, Weimin
    Zou, Yinghua
    Xie, Shuanghua
    Zhang, Jianwei
    Yuan, Wei
    Ma, Jie
    Zhao, Jiuda
    Zheng, Cuiling
    Chen, Yingtai
    Wang, Chengfeng
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 5965 - 5978
  • [7] Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
    Marwan Ghosn
    Tony Ibrahim
    Tarek Assi
    Elie El Rassy
    Hampig Raphael Kourie
    Joseph Kattan
    World Journal of Gastroenterology, 2016, (46) : 10124 - 10130
  • [8] Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
    Ghosn, Marwan
    Ibrahim, Tony
    Assi, Tarek
    El Rassy, Elie
    Kourie, Hampig Raphael
    Kattan, Joseph
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (46) : 10124 - 10130
  • [9] Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy
    Ueno, H
    Okada, S
    Okusaka, T
    Ikeda, M
    ONCOLOGY, 2000, 59 (04) : 296 - 301
  • [10] Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.
    Laurent-Badr, Q.
    Barbe, C.
    Brugel, M.
    Hautefeuille, V
    Volet, J.
    Grelet, S.
    Desot, E.
    Botsen, D.
    Deguelte, S.
    Pitta, A.
    Abdelli, N.
    Brasseur, M.
    De Mestier, L.
    Neuzillet, C.
    Bouche, O.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (06) : 658 - 667
12345